Open AccessThis article is
- freely available
Familial Pancreatic Cancer
Department of Preventive Medicine and Public Health, Creighton University, 2500 California Plaza, Omaha NE 68178, USA
Department of Gastroenterology, Creighton University, 2500 California Plaza, Omaha NE 68178, USA
* Author to whom correspondence should be addressed.
Received: 12 October 2010; in revised form: 3 November 2010 / Accepted: 4 November 2010 / Published: 10 November 2010
Abstract: Pancreatic cancer’s high mortality rate equates closely with its incidence, thereby showing the need for development of biomarkers of its increased risk and a better understanding of its genetics, so that high-risk patients can be better targeted for screening and early potential lifesaving diagnosis. Its phenotypic and genotypic heterogeneity is extensive and requires careful scrutiny of its pattern of cancer associations, such as malignant melanoma associated with pancreatic cancer, in the familial atypical multiple mole melanoma syndrome, due to the CDKN2A germline mutation. This review is designed to depict several of the hereditary pancreatic cancer syndromes with particular attention given to the clinical application of this knowledge into improved control of pancreatic cancer.
Keywords: phenotypic and genotypic heterogeneity; high mortality; genetic counseling; biomarker paucity; FAMMM syndrome; Li-Fraumeni syndrome; Lynch syndrome; pancreatic cancer
Citations to this Article
Cite This Article
MDPI and ACS Style
Lynch, H.T.; Lynch, J.F.; Lanspa, S.J. Familial Pancreatic Cancer. Cancers 2010, 2, 1861-1883.
Lynch HT, Lynch JF, Lanspa SJ. Familial Pancreatic Cancer. Cancers. 2010; 2(4):1861-1883.
Lynch, Henry T.; Lynch, Jane F.; Lanspa, Stephen J. 2010. "Familial Pancreatic Cancer." Cancers 2, no. 4: 1861-1883.